The Food and Drug Administration requested that Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX) submit positive data from an additional study of Firdapse in Lambert-Eaton myasthenia syndrome patients. Shares of the biopharmaceutical plunged 65 cents to $0.59.
FDA requests additional data from Catalyst Pharmaceuticals
April 26, 2016 at 12:48 PM EDT
